Myasthenia gravis is an autoimmune neuromuscular disease leading to fluctuating muscle weakness and fatiguability. It is an autoimmune disorder, in which weakness is caused by circulating antibodies that block acetylcholine receptors at the post-synaptic neuromuscular junction inhibiting the stimulative effect of the neurotransmitter acetylcholine.
The hallmark of Myasthenia Gravis is fatigability. Muscles become progressively weaker during periods of activity and improve after periods of rest. Muscles that control eye and eyelid movement, facial expressions, chewing talking and swallowing are especially susceptible. The muscles that control breathing and neck and limb movements can also be affected. Often the physical examination yields results within normal limits. The onset of the disorder can be sudden. Often symptoms are intermittent. The diagnosis of Myasthenia Gravis may be delayed if the symptoms are subtle or variable.
To treat the disease, clinician first destroy the patients own immune cells with chemotherapy, then gives them purified blood forming stem cells. The modified stem cells then build new bone marrow, thus restoring the correct signaling pattern to the immune system and the immune system now has cells that do not attack the body. This may lead to significant improvement in the lifestyles and symptom of the patient, Significantly improving the quality of life.